Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNIPER: Image Guided Surgery in Sinonasal Inverted Papilloma
NCT03925285Phase 1Unknown
- Sponsor
- University Medical Center Groningen
- Start
- May 2019
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bevacizumab-IRDye800CW in sinonasal inverted papilloma, sponsored by University Medical Center Groningen. Primary endpoint: Tumor-to-background ratio of mean fluorescence intensity. Status: unknown.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
sinonasal inverted papilloma
Beyond the preview
Go deeper on NCT03925285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03925285.